Liminatus Pharma, Inc. (LIMN)
CIK 1971387 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 44.9M shares as of May 14, 2026 (10-Q).
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Common Stock Purchase Warrants | 13.8M | $0.29 | 5y | — |
| Pre Funded Warrants | 5.5M | $0.0001 | — | — |
| Public Warrants | 5.1M | $0.01 | 0.1y | — |
| Private Placement Warrants | 835,555 | not tagged | — | — |
| Placement Agent Warrants | 690,650 | $0.319 | 5y | — |
| Non Redeemable Warrant | not tagged | $11.5 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 15, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 1 underlying shares, as reported Jun 30, 2025 (10-Q).
Reported exercise price: $11.5 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $33,422 as of Mar 31, 2026.
Rough fully diluted estimate: 44.9M = 44.9M O/S + 1 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed May 15, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 44.9M | May 14, 2026 |
| + Common Stock Purchase Warrants (if exercised) | 13.8M | Mar 31, 2026 |
| + Pre Funded Warrants (if exercised) | 5.5M | Feb 18, 2026 |
| + Public Warrants (if exercised) | 5.1M | Mar 31, 2026 |
| + Private Placement Warrants (if exercised) | 835,555 | Mar 31, 2026 |
| + Placement Agent Warrants (if exercised) | 690,650 | Mar 31, 2026 |
| Fully diluted estimate | 70.9M | +57.9% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $28.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 4 executed · 2 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full LIMN workspace